Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Trends Cancer. 2022 Aug;8(8):629-631. doi: 10.1016/j.trecan.2022.05.003. Epub 2022 Jun 4.
Checkpoint blockade and adoptive T cell therapy are efficacious in some patients, but many do not respond to these immunotherapies. Chou et al. recently elucidated the characteristics of a new cell population with greater cytotoxicity, improved tumor homing, and reduced exhaustion compared to conventional cytotoxic T cells. These cells may improve the efficacy of cancer immunotherapies, especially for patients refractory or unresponsive to current approaches.
检查点阻断和过继性 T 细胞疗法在一些患者中有效，但许多患者对这些免疫疗法没有反应。Chou 等人最近阐明了一种新的细胞群体的特征，与传统的细胞毒性 T 细胞相比，这种细胞具有更强的细胞毒性、改善的肿瘤归巢能力和减少的衰竭。这些细胞可能提高癌症免疫疗法的疗效，特别是对于对当前方法有抗药性或无反应的患者。
